A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
The goal of this study is to learn if emvistegrast (formerly GS-1427) is effective in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with emvistegrast with participants treated with placebo.
The primary objective of this study is to assess the efficacy of emvistegrast, compared with placebo control, in achieving clinical response at Week 12.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Miami, Florida 33136, United States
Chicago, Illinois 60637, United States
Wyoming, Michigan 49519, United States
South Brisbane, Queensland 4101, Australia
Vienna, 1090, Austria
La Tronche, 38700, France
Pierre-Bénite, 69495, France
Dresden, 01307, Germany
Békéscsaba, 5600, Hungary
San Giovanni Rotondo, 71013, Italy
Kelantan, 16150, Malaysia
Dunedin, 9012, New Zealand
Mazowieckie, 05-500, Poland
Cluj-Napoca, 400132, Romania
Belgrade, 11000, Serbia
Belgrade, 11000, Serbia
Belgrade, 11000, Serbia
Belgrade, 112108, Serbia
Kragujevac, 34000, Serbia
Zrenjanin, 23000, Serbia
Jongno-Gu, 03181, South Korea
Nam-Gu, 42415, South Korea
Seongdong-gu, 4763, South Korea